TME Pharma
TME Pharma is a clinical-stage company focusing on developing novel therapies for treatment of the most aggressive cancers. We specialize in approaches targeting the tumor microenvironment (TME) in which cancer cells exist. Our unique technology breaks tumor protection barriers against the immune system and blocks tumor repair by neutralizing chemokines in the TME. TME Pharma’s approach works in combination with other forms of treatment to weaken tumor defenses and enable greater therapeutic impact. Our clinical programs in glioblastoma and pancreatic cancer have delivered very promising results and further development is planned.
|
Updated corporate presentation with ESMO 15 Sept 2024 Oral Presentation data showing statistically significant improvement in survival
|
Press Release2025, April 10 07:00 p.m. TME Pharma provides update on resources allocated to the liquidity contract with Invest Securities 2025, March 28 06:00 p.m. TME Pharma provides results of fifth exercise of Warrants Z 2025, March 13 06:00 p.m. TME Pharma announces filing of patents for use of CCL2 inhibitor NOX-E36 in ophthalmology and presentation at ARVO 2025 of preclinical data showing benefit in glaucoma filtration surgery |
EventsNEAUX CANCER 4th ANNUAL CAGLA CONFERENCE
Aram Mangasarian Latest Analyst ReportInvest Securities |